Hashimoto, Mamoru
Manabe, Yuta
Yamaguchi, Takuhiro
Toya, Shunji
Ikeda, Manabu
Funding for this research was provided by:
Sumitomo Pharma Co., Ltd. (Not applicable.)
Article History
Received: 23 August 2022
Accepted: 23 November 2022
First Online: 15 December 2022
Change Date: 5 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13195-022-01155-9
Declarations
:
: After approval by the Observational Study Ethics Committee of Osaka University Hospital (IRB No., 20171-4, November 11, 2020), this study was conducted in compliance with the ethical principles of the Declaration of Helsinki (revised in 2013), the Ethical Guidelines for Medical and Health Research Involving Human Subjects (partially revised in 2017), and the research protocol. This study was registered at UMIN Clinical Trials Registry under the identifier number UMIN000041844. Written informed consent was obtained from all patients and their caregivers. Physicians consented to participate in this study via the web.
: Not applicable.
: MH has received travel expenses from Sumitomo Pharma Co., Ltd. YM has received research funding and travel expenses from Sumitomo Pharma Co., Ltd. ST is an employee of Sumitomo Pharma Co., Ltd. MI has received research funding from Sumitomo Pharma Co., Ltd. TY has no competing interest to disclose.